Results 41 to 50 of about 13,054 (213)

Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice

EMBO Molecular Medicine, 2013
HDAC inhibitors (HDACi) exert beneficial effects in mdx mice, by promoting endogenous regeneration; however, the cellular determinants of HDACi activity on dystrophic muscles have not been determined.
Chiara Mozzetta, Silvia Consalvi, Valentina Saccone, Matthew Tierney, Adamo Diamantini, Kathryn J. Mitchell, Giovanna Marazzi, Giovanna Borsellino, Luca Battistini, David Sassoon, Alessandra Sacco, Pier Lorenzo Puri   +11 more
doaj   +1 more source

HDACi induces apoptosis of osteosarcoma cells by inhibiting the MAPK pathway. [PDF]

Sci Rep
Investigate the malignant biological effects of the histone deacetylase inhibitor (HDACi) in osteosarcoma (OS) and study the underlying mechanisms through mRNA sequencing. CCK-8, colony formation, Transwell assays, live/dead staining, and flow cytometry were used to observe the malignant biological effects of 4-phenylbutyric acid (4-PA) on OS cells ...
Qin C, Lin TT, Lin YM, Zhang YL, Hong SJ, Jia X, Liu WG.   +6 more
europepmc   +3 more sources

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation

Frontiers in Oncology
Histone deacetylase inhibitors (HDAC inhibitors, HDACi) have garnered considerable attention due to their potential in treating various types of malignant tumors.
Jiaqi Tian, Jiaqi Tian, Miaomiao Han, Fuyang Song, Yun Liu, Yuhou Shen, Jiateng Zhong, Jiateng Zhong, Jiateng Zhong   +8 more
doaj   +1 more source

Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. [PDF]

PLoS ONE, 2009
Histone deacetylase inhibitors (HDACi) have demonstrated promising therapeutic potential in clinical trials for hematological malignancies. HDACi, such as SAHA/Vorinostat, Trichostatin A, and MS-275 were found to induce apoptosis of leukemic blasts ...
Bérengère Vire, Stéphane de Walque, Audrey Restouin, Daniel Olive, Carine Van Lint, Yves Collette   +5 more
doaj   +1 more source

Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Peripheral blood single‐cell RNA‐seq from leukaemic CTCL defined three malignant T‐cell programmes: MTC CM, MTC Reg and MTC E/EM, each with distinct features and candidate vulnerabilities. For example, inferred immune circuits highlighted actionable IL‐10/JAK–TYK2–STAT3 signalling, KIR–MHC I inhibitory interactions and myeloid/B‐cell inflammatory and ...
Beth A. Childs, Eslam A. Elghonaimy, Praveen Ramakrishnan Geethakumari, Kiran A. Kumar, Joseph F. Merola, Heather W. Goff, Todd A. Aguilera   +6 more
wiley   +1 more source

HDACi-induced EMT phenotype.

, 2013
Schematic drawing of the proposed mechanism by which chromatin acetylation influences head and neck tumor behavior. Tumors with hypoacetylated chromatin (low levels of Ac. H3) accumulate and maintain CSC.
Rogerio M. Castilho (364759), Jacques E. Nör (392053), Decio S. Pinto Jr (392052), Fernanda S. Giudice (392051), Cristiane H. Squarize (364756)   +4 more
core   +1 more source

Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. [PDF]

PLoS ONE, 2014
We have previously used the ATAD5-luciferase high-throughput screening assay to identify genotoxic compounds with potential chemotherapeutic capabilities.
Stephanie Smith, Jennifer Fox, Marco Mejia, Wanvipa Ruangpradit, Alihossein Saberi, Sunmi Kim, Yongjun Choi, Sehyun Oh, Yucai Wang, Kyungho Choi, Lei Li, Eric A Hendrickson, Shunichi Takeda, Mark Muller, Kyungjae Myung   +14 more
doaj   +1 more source

Epigenetic Regulation in the Pathogenesis of Periodontitis

Journal of Periodontal Research, EarlyView.
The aim of this narrative literature review was to identify epigenetic marks associated with periodontitis and to place them in a biological context. The literature was reviewed based on pre‐defined criteria. Cell type specific chromatin and mRNA modifications were included.
Henrik Dommisch, Arne Sönke Schäfer, Denica Kuzmanova, Dominique S. Michaud   +3 more
wiley   +1 more source

Histone Deacetylase Inhibitors Promote the Anticancer Activity of Cisplatin: Mechanisms and Potential

Pharmaceuticals
Cisplatin is a widely used DNA-targeting anticancer drug. Histone deacetylase inhibitors (HDACi) cause histone hyperacetylation, changing chromatin structure and accessibility of genomic DNA by the genotoxic drug.
Yang Zhou, Qun Luo, Liangzhen Gu, Xiao Tian, Yao Zhao, Yanyan Zhang, Fuyi Wang   +6 more
doaj   +1 more source